Tengion is developing a diverse pipeline of novel cell and tissue based regenerative medicine therapies for patients who are experiencing organ and tissue impairment, failure and loss. Tengion's technology platform is designed to allow patients to have functioning organs and tissues regenerated from their own cells, resulting in improved quality of life for patients, reduced comorbidities, and ultimately reduced use of medical system resources.
Tengion is supporting the clinical development of the following product candidates:
Tengion's Organ Regeneration Platform has the potential to identify product candidates for several gastrointestinal and vascular diseases and conditions. Partnership opportunities are being explored for the following product candidates (not in active development):
Tengion's regenerative medicine product candidates are investigational and will not be commercially available until the completion of clinical trials and the review and approval of associated marketing applications by the U.S. Food and Drug Administration or competent regulatory agencies in other countries.